Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Florbetapir F18 PET Amyloid Neuroimaging and Characteristics in Patients With Mild and Moderate Alzheimer Dementia.

Degenhardt EK, Witte MM, Case MG, Yu P, Henley DB, Hochstetler HM, D'Souza DN, Trzepacz PT.

Psychosomatics. 2016 Mar-Apr;57(2):208-16. doi: 10.1016/j.psym.2015.12.002. Epub 2015 Dec 3.

2.

Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.

Hochstetler H, Trzepacz PT, Wang S, Yu P, Case M, Henley DB, Degenhardt E, Leoutsakos JM, Lyketsos CG.

J Alzheimers Dis. 2016;50(1):271-82. doi: 10.3233/JAD-150563.

3.

Alzheimer's disease progression by geographical region in a clinical trial setting.

Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J.

Alzheimers Res Ther. 2015 Jun 25;7(1):43. doi: 10.1186/s13195-015-0127-0. eCollection 2015.

4.

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials.

Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL.

Alzheimers Res Ther. 2015 Jun 25;7(1):39. doi: 10.1186/s13195-015-0122-5. eCollection 2015.

5.

Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings.

Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC.

Curr Med Res Opin. 2014 Oct;30(10):2021-32. doi: 10.1185/03007995.2014.939167. Epub 2014 Jul 14.

PMID:
24983746
6.

Adverse events and dropouts in Alzheimer's disease studies: what can we learn?

Henley DB, Sundell KL, Sethuraman G, Schneider LS.

Alzheimers Dement. 2015 Jan;11(1):24-31. doi: 10.1016/j.jalz.2013.11.008. Epub 2014 Mar 6.

PMID:
24613705
7.

Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies.

Henley DB, Sundell KL, Sethuraman G, Siemers ER; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2012 Sep;8(5):407-16. doi: 10.1016/j.jalz.2011.05.2413. Epub 2011 Dec 3.

PMID:
22138370
8.

Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

Henley DB, May PC, Dean RA, Siemers ER.

Expert Opin Pharmacother. 2009 Jul;10(10):1657-64. doi: 10.1517/14656560903044982. Review.

PMID:
19527190
9.

An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.

Trivedi MH, Thase ME, Osuntokun O, Henley DB, Case M, Watson SB, Campbell GM, Corya SA.

J Clin Psychiatry. 2009 Mar;70(3):387-96. Epub 2009 Mar 10.

PMID:
19284928
10.

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.

Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, Watson SB, Dubé S.

J Clin Psychiatry. 2007 Feb;68(2):224-36.

PMID:
17335320

Supplemental Content

Loading ...
Support Center